Efeitos do tratamento não cirúrgico da periodontite crônica sobre marcadores inflamatórios em pacientes com doença renal crônica

Abstract

This is an interventional controlled clinical assay. The aim of this study was to determine the impact of periodontal treatment (PT) on the systemic markers of inflammation and to determine a correlation betwen serum level of prohepcidin (prohormone of hepcidin) and chronic periodontitis (CP) in patients with chronic kidney disease (CKD) who were not yet under dialysis. This study included 56 patients with CP moderate to severe, 36 with CKD (CKD group) and 20 without systemic diseases and with normal renal function (control group). CKD was defined as suggested by the K/DOQI of National Kidney Foundation. CP was defined by the clinical attachment level (CAL) and the probing pocket depth (PPD), according to the American Association of Periodontology (AAP). The participants received no surgical periodontal treatment and inflammatory markers ultrasensitive C-reactive protein (us- PCR), interleukin-6 (IL-6), and prohepcidin were evaluated before and 3 months after PT. The results proven effective PT was by measuring decreases in CAL and PPD following PT in the control (2,37±0,40 vs. 2,02± 0,43, p <0,05 and 2,52±0,41 vs. 1,98± 0,40, p <0,05), and CKD groups (2,92±0,92 vs. 2,20± 0,65, p <0,05 and 2,90±1,13 vs. 1,99± 0,82, p <0,05). PT resulted in a statistically significant reduction in us-PCR and IL-6 levels in both groups. Additionally, there was a significant fall in serum prohepcidin (ng/mL) after PT in the control group (147.39±5150 vs. 131.72±47.10, p<0.01) and CKD group (166.24±55.70 vs. 153.29±56.90, p<0.05). Moreover, in multivariated linear regression, the reduction of prohepcidin levels after PT was significantly and independently associated with IL-6 levels (p=0.02) in the control group. However, in conclusion CP moderate to severe in patients with CKD, can determine increase in the systemic inflammatory response. Successful PT, by inducing a decline in the systemic inflammatory burden and a decrease in serum prohepcidin. This terapy might constitute an important intervention in ameliorating of the inflammation seen in patients with CKD.